Legitimate questions about the virus created perfect conditions for conspiracy theories. In the absence of knowledge, guesswork and propaganda flourished

In December last year, Sanofi had said it was targeting \"earliest potential approval\" of the shot in the second half of 2021, following positive preclinical data

Russia began testing EpiVacCorona, which is being developed by Siberia's Vector Institute, in November

(For) all our vaccines, we are looking at right now..(we) are targeting 2-8 degree because our logistics are worked out on that basis and we are working on that, DBT secretary Renu Swarup said at a press briefing

TCS, ONGC, SBI, L&T, Infosys, HCL Tech, ICICI Bank and Axis Bank were among the gainers. On the other hand, HDFC, Asian Paints and Reliance Industries were among the laggards

Coronavirus vaccine in India: Adar Poonawalla, CEO of Serum Institute of India that is manufacturing Covishield had said that the company is ready to roll out its vaccine in the coming weeks

Cadila Healthcare share touched an intraday high of Rs 492.95, rising 3.02% against previous close of Rs 478.50 on BSE

COVID-19 vaccine in India: It would make every Indian proud that the two vaccines that have been given emergency use approval are made in India! This shows the eagerness of our scientific community to fulfil the dream of an Aatmanirbhar Bharat, said PM Modi

COVID-19 vaccines in India: Oxford-AstraZeneca's coronavirus vaccine Covishield and Bharat Biotech's COVID vaccine Covaxin will be India's first vaccines

This development comes hours after the UK government accepted the recommendation from the Medicines and Healthcare Regulatory Agency (MHRA) to authorise Oxford University-AstraZeneca's Covid-19 vaccine, named Covishield, for emergency use

Covaxin can protect against COVID-19 mutant: Bharat Biotech Covaxin, a vaccine candidate being developed by Bharat Biotech for COVID-19, can offer protection against mutations of coronavirus, Chairman and Managing Director of the city-based vaccine maker, Krishna Ella, said on Tuesday. He also said the company has approached regulatory authorities seeking approval for an emergency license to use the vaccine, developed in collaboration with the Indian Council of Medical Research (ICMR) and t...

Bharat Biotech MD also said the company has approached regulatory authorities seeking approval for an emergency license to use the vaccine, developed in collaboration with ICMR and the National Institute of Virology and now undergoing phase 3 trials

Poonawalla says Covishield shows efficacy level of 95 per cent provided two shots are taken after a gap of 2-3 months; AstraZeneca will make that public with documentation soon, he adds

The vaccine development process by Bharat Biotech, Biological E Ltd and Aurobindo Pharma are currently in various stages, while Dr Reddy's and Hetero have tie ups for manufacturing the vaccine

Delhi Chief Minister Arvind Kejriwal said that the capital is fully ready to receive, store and give coronavirus vaccine to \"priority category\" people in the first phase of vaccination; Air India pilots have refused to accept the 'paltry' 5 per cent roll back in the 'illegal pay cut' by the carrier; All India Institute of Medical Sciences, one of the sites for the coronavirus vaccine trials for Bharat Biotech's candidate Covaxin, has put up advertisements inviting volunteers to enroll for the Phase 3 trials. Watch this and more on News Blast.Also Read: COVID stress boosts digital selling among micro, small enterprises: CRISIL

The SII CEO says considering the high demand for vaccines in the wake of coronavirus, the next decade could be a \"golden one\" for the entire vaccine industry

COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate, named UB-612; vaccine's main advantage is that it uses normal refrigeration for distribution

World's biggest vaccine maker has already manufactured over 50 million doses; further production will start as soon as it gets necessary approvals in India and the UK. SII is hoping to supply 3 billion doses of vaccine in 2021

In his latest blog post, Bill & Melinda Gates Foundation co-chairman said his foundation has also taken some of the financial risks on the Oxford-AstraZeneca vaccine and that Serum won't have to take a full loss

SII had earlier said its vaccine candidate showed 90 per cent efficacy rate at a full dose plus a half dose regimen, while a 62 per cent efficacy rate at full two-dose regimen